Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 85,291 |
|
|||||
| News | - | ||||||
| Day High | 3.68 | Low High |
|||||
| Day Low | 3.5001 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| ARCA Biopharma Inc | ABIO | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.10 | 2.87% | 3.58 | 16:30:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.68 | 3.5001 | 3.68 | 3.58 | 3.48 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 363 | 85,291 | $ 3.61 | $ 307,724 | - | 1.56 - 3.88 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:37:23 | 10 | $ 3.55 | USD |
ARCA Biopharma Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 51.48M | 14.50M | - | 0 | -5.34M | -0.37 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
ARCA Biopharma News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ABIO Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.24 | 3.75 | 3.21 | 3.46 | 316,318 | 0.34 | 10.49% |
| 1 Month | 1.78 | 3.88 | 1.6901 | 3.24 | 4,645,271 | 1.80 | 101.12% |
| 3 Months | 1.57 | 3.88 | 1.57 | 3.23 | 1,539,105 | 2.01 | 128.03% |
| 6 Months | 1.97 | 3.88 | 1.56 | 3.20 | 727,573 | 1.61 | 81.73% |
| 1 Year | 1.96 | 3.88 | 1.56 | 3.16 | 372,990 | 1.62 | 82.65% |
| 3 Years | 3.51 | 3.90 | 1.56 | 2.97 | 228,493 | 0.07 | 1.99% |
| 5 Years | 5.43 | 22.00 | 1.56 | 7.32 | 395,915 | -1.85 | -34.07% |
ARCA Biopharma Description
| ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. |
